Aβ oligomers induce glutamate release from hippocampal neurons

Current Alzheimer Research

Volumn 8, Issue 5, 2011, Pages 552-562

  Brito Moreira, J ^a   Paula Lima, A C ^a,e   Bomfim, T R ^a   Oliveira, F F ^a   Sepulveda F J ^d   de Mello, F G ^b   Aguayo, L G ^d   Panizzutti, R ^c   Ferreira, S T ^a,c  

^a Institute of Medical Biochemistry   (Brazil)

^b Institute of Biophysics Carlos Chagas Filho   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF CONCEPCIÓN   (Chile)

^e Centro FONDAP Estudios Moleculares de la Celula   (Chile)

Author keywords

A ; Alzheimer's disease; D serine; Glutamate; Oligomers; Taurine

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLOID BETA PROTEIN; DEXTRO SERINE; DIZOCILPINE; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TAURINE; TETRODOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; INHIBITION KINETICS; NONHUMAN; PATCH CLAMP; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION; RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUTAMIC ACID; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; NEURONS; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79959762240     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511796391917     Document Type: Article

References (71)

1. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 18: 10417-10422 (2003).
2. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 5: 1172-1184 (2007).
3. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 1: 106-113 (2008).
4. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synap-tic change in Alzheimer's disease. Am J Pathol 3: 853-862 (1999).
5. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 6: 860-866 (1999).
6. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 2: 328-337 (1999).
7. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer's-related amyloid beta oli-gomers. J Neurosci 45: 10191-10200 (2004).
8. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 4: 796-807 (2007).
9. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2: 101-112 (2007).
10. Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 4-5: 332-345 (2007).
11. Viola KL, Velasco PT, Klein WL. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging 1: 51S-57S (2008).
12. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Lio-satos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 11: 6448-6453 (1998).
13. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 6880: 535-539 (2002).
14. Cheng L, Yin WJ, Zhang JF, Qi JS. Amyloid beta-protein fragments 25-35 and 31-35 potentiate long-term depression in hippo-campal CA1 region of rats in vivo. Synapse 3: 206-214 (2009).
15. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 6: 788-801 (2009).
16. de Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 6: 1971-1976 (2009).
17. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430(7000), 631-639 (2004).
18. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2: 160-170 (2006).
19. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 9: 454-463 (2008).
20. Alberdi E, Sanchez-Gomez MV, Cavaliere F, Perez-Samartin A, Zugaza JL, Trullas R, et al. Amyloid beta oligomers induce Ca(2+) dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47: 264-272 (2010).
21. Sanchez-Prieto J, Budd DC, Herrero I, Vazquez E, Nicholls DG. Presynaptic receptors and the control of glutamate exocytosis. Trends Neurosci 6: 235-239 (1996).
22. Rosenmund C, Rettig J, Brose N. Molecular mechanisms of active zone function. Curr Opin Neurobiol 5: 509-519 (2003).
23. Palmada M and Centelles JJ. Excitatory amino acid neurotransmis-sion. Pathways for metabolism, storage and reuptake of glutamate in brain. Front Biosci 3: d701-d718 (1998).
24. Ikematsu K, Tsuda R, Kondo T, Nakasono I. The expression of excitatory amino acid transporter 2 in traumatic brain injury. Forensic Sci Int 2-3: 83-89 (2002).
25. Zhou J, Sutherland ML. Glutamate transporter cluster formation in astrocytic processes regulates glutamate uptake activity. J Neurosci 28: 6301-6306 (2004).
26. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M, et al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 8: 2735-2745 (2000).
27. Harris ME, Wang Y, Pedigo NW Jr., Hensley K, Butterfield DA, Carney JM. Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neuro-chem 1: 277-286 (1996).
28. Parpura-Gill A, Beitz D, Uemura E. The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res 1(2): 65-71 (1997).
29. Noda M, Nakanishi H, Akaike N. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 4: 1465-1474 (1999).
30. de Ceballos ML, Brera B, Fernandez-Tome MP. Beta-Amyloid-induced cytotoxicity, peroxide generation and blockade of glutamate uptake in cultured astrocytes. Clin Chem Lab Med 4: 317-318 (2001).
31. Fernandez-Tome P, Brera B, Arevalo MA, de Ceballos ML. Beta-amyloid25-35 inhibits glutamate uptake in cultured neurons and as-trocytes: modulation of uptake as a survival mechanism. Neurobiol Dis 3: 580-589 (2004).
32. de Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 15: 11590-11601 (2007).
33. Kartvelishvily E, Shleper M, Balan L, Dumin E, Wolosker H. Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J Biol Chem 20: 14151-14162 (2006).
34. De Felice FG, Houzel JC, Garcia-Abreu J, Louzada PR Jr., Afonso RC, Meirelles MN, et al. Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by ni-trophenols: implications for Alzheimer's therapy. FASEB J 7: 1297-1299 (2001).
35. Paula-Lima AC, De Felice FG, Brito-Moreira J, Ferreira ST. Activation of GABA(A) receptors by taurine and muscimol blocks the neurotoxicity of beta-amyloid in rat hippocampal and cortical neurons. Neuropharmacology 8: 1140-1148 (2005).
36. Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, Magdesian MH, et al. Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol 6: 1361-1370 (2009).
37. Hashimoto A, Nishikawa T, Oka T, Takahashi K, Hayashi T. Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-L-cysteine and ophthaldialdehyde. J Chromatogr 1-2: 41-48 (1992).
38. Velasco I, Tapia R, Massieu L. Inhibition of glutamate uptake induces progressive accumulation of extracellular glutamate and neuronal damage in rat cortical cultures. J Neurosci Res 6: 551-561 (1996).
39. Nicholls D, Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol Sci 11: 462-468 (1990).
40. Hashimoto A, Nishikawa T, Oka T, Takahashi K, Hayashi T. Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-L-cysteine and o-phthaldialdehyde. J Chromatogr 1-2: 41-48 (1992).
41. Oertel WH, Schmechel DE, Tappaz ML, Kopin IJ. Production of a specific antiserum to rat brain glutamic acid decarboxylase by injection of an antigen-antibody complex. Neuroscience 12: 2689-2700 (1981).
42. Bergles DE, Dzubay JA, Jahr CE. Glutamate transporter currents in bergmann glial cells follow the time course of extrasynaptic gluta-mate. Proc Natl Acad Sci USA 26: 14821-14825 (1997).
43. Mennerick S, Shen W, Xu W, Benz A, Tanaka K, Shimamoto K, et al. Substrate turnover by transporters curtails synaptic glutamate transients. J Neurosci 21: 9242-9251 (1999).
44. Benson DL, Watkins FH, Steward O, Banker G. Characterization of GABAergic neurons in hippocampal cell cultures. J Neurocytol 5: 279-295 (1994).
45. Velasco I, Tapia R, Massieu L. Inhibition of glutamate uptake induces progressive accumulation of extracellular glutamate and neuronal damage in rat cortical cultures. J Neurosci Res 6: 551-561 (1996).
46. Shigeri Y, Shimamoto K, Yasuda-Kamatani Y, Seal RP, Yumoto N, Nakajima T, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem 2: 297-302 (2001).
47. Nicholls D, Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol Sci 11: 462-468 (1990).
48. Jia F, Yue M, Chandra D, Keramidas A, Goldstein PA, Homanics GE, et al. Taurine is a potent activator of extrasynaptic GABA(A) receptors in the thalamus. J Neurosci 1: 106-115 (2008).
49. Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal 11-12: 1997-2006 (2006).
50. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 11: 2866-2875 (2007).
51. Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG. Beta-amyloid causes depletion of synaptic vesicles leading to neu-rotransmission failure. J Biol Chem 4: 2506-2514 (2010).
52. Shi C, Wu F, Xu J. H2O2 and PAF mediate Abeta1-42-induced Ca2+ dyshomeostasis that is blocked by EGb761. Neurochem Int 8: 893-905 (2010).
53. Bobich JA, Zheng Q, Campbell A. Incubation of nerve endings with a physiological concentration of Abeta1-42 activates CaV2.2(N-Type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. J Alzheimers Dis 3: 243-255 (2004).
54. Harkany T, Abraham I, Laskay G, Timmerman W, Jost K, Zarandi M, et al. Propionyl-IIGL tetrapeptide antagonizes beta-amyloid ex-citotoxicity in rat nucleus basalis. Neuroreport 8: 1693-1698 (1999).
55. Amatniek JC, Hauser WA, del Castillo-Castaneda C, Jacobs DM, Marder K, Bell K, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 5: 867-872 (2006).
56. Yang Y, Ge W, Chen Y, Zhang Z, Shen W, Wu C, et al. Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci USA 25: 15194-15199 (2003).
57. Mothet JP, Parent AT, Wolosker H, Brady RO, Jr., Linden DJ, Ferris CD, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 9: 4926-4931 (2000).
58. Mothet JP, Rouaud E, Sinet PM, Potier B, Jouvenceau A, Dutar P, et al. A critical role for the glial-derived neuromodulator D-serine in the age-related deficits of cellular mechanisms of learning and memory. Aging Cell 3: 267-274 (2006).
59. Shleper M, Kartvelishvily E, Wolosker H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organo-typic hippocampal slices. J Neurosci 41: 9413-9417 (2005).
60. Wolosker H, Sheth KN, Takahashi M, Mothet JP, Brady RO, Ferris CD, et al. Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA 2: 721-725 (1999).
61. Panizzutti R, De Miranda J, Ribeiro CS, Engelender S, Wolosker H. A new strategy to decrease N-methyl-D-aspartate (NMDA) receptor coactivation: inhibition of D-serine synthesis by converting serine racemase into an eliminase. Proc Natl Acad Sci USA 9: 5294-5299 (2001).
62. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L, et al. Targeted disruption of serine racemase affects glutamatergic neuro-transmission and behavior. Mol Psychiatry 7: 719-727 (2009).
63. Vargas-Lopes C, Madeira C, Kahn SA, do Couto IA, Bado P, Houzel JC, et al. Protein kinase C (PKC) activity regulates D-serine availability in the brain. J Neurochem 116(2): 281-90 (2010).
64. Williams SM, Diaz CM, Macnab LT, Sullivan RK, Pow DV. Im-munocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons. Glia 4: 401-411 (2006).
65. Rosenberg D, Kartvelishvily E, Shleper M, Klinker CM, Bowser MT, Wolosker H. Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration. FASEB J 8: 2951-2961 (2010).
66. Wu SZ, Bodles AM, Porter MM, Griffin WS, Basile AS, Barger SW. Induction of serine racemase expression and D-serine release from microglia by amyloid beta-peptide. J Neuroinflammation 1: 2 (2004).
67. Inoue R, Hashimoto K, Harai T, Mori H. NMDA- and beta-amyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice. J Neurosci 53: 14486-14491 (2008).
68. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 13: 4004-4015 (2009).
69. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 5: 697-711 (2007).
70. Louzada PR, Paula Lima AC, Mendonca-Silva DL, Noel F, de Mello FG, Ferreira ST. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J 3: 511-518 (2004).
71. Paula-Lima AC, Louzada PR, de Mello FG, Ferreira ST. Neuro-protection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? Neurotox Res 5: 323-327 (2003).